BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
BioVie announced it will host a virtual KOL event on May 7, 2026, featuring Dr. Suzanne de la Monte to discuss the mechanism of action and Phase 2 trial of bezisterim for Parkinson's disease. The company remains on track for topline data from the Parkinson's study in mid-2026, while also enrolling about 200 patients for its ADDRESS-LC trial in Long COVID.
Key figures
- Topline data timing
- mid-2026
- Long covid enrollment
- about 200 patients
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.